TIEMONIUM MESYLATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H24NO2S.CH3O3S
Molecular Weight	413.551
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS([O-])(=O)=O.C[N+]3(CCC(O)(C1=CC=CS1)C2=CC=CC=C2)CCOCC3

InChI

InChIKey=AVROMTYQGLLKRH-UHFFFAOYSA-M

InChI=1S/C18H24NO2S.CH4O3S/c1-19(11-13-21-14-12-19)10-9-18(20,17-8-5-15-22-17)16-6-3-2-4-7-16;1-5(2,3)4/h2-8,15,20H,9-14H2,1H3;1H3,(H,2,3,4)/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula	C18H24NO2S
Molecular Weight	318.454
Charge	1
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	CH3O3S
Molecular Weight	95.098
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF | https://www.ncbi.nlm.nih.gov/pubmed/187134

Tiemonium (often used in a form of iodide or methylsulphate salt) is a muscarinic acetylcholine receptor antagonist, which is available in Asia (mainly Bangladesh) for the alleviation of muscle spasms of the intestine, biliary system, uterus and urinary bladder in gastrointestinal, biliary, urinary and gynecological diseases.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8822036 \| https://www.ncbi.nlm.nih.gov/pubmed/187134	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Gastroenteritis 10 Sources: http://www.squarepharma.com.bd/downloads/Norvis.pdf	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Diarrhea 35 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Dysentery 7 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Biliary colic 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Enterocolitis 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Cholecystitis 12 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Colonopathies 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Mild cystitis 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Spasmodic dysmenorrhoea 4 Sources: http://www.squarepharma.com.bd/downloads/Norvis%20DS.PDF	Palliative	Approved 8429	NORVIS Approved Use Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.

PubMed

Title	Date	PubMed
Orofacial dyskinesia associated with tiemonium.	2007 Dec	18034667
Direct asymmetric catalytic thienylaluminum addition to ketones: a concise approach to the synthesis of (S)-tiemonium iodide.	2009 Aug 6	19588914
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
6,7-Difluoro-1,4-dihydro-1-methyl-4-oxo-3-quinolinecarboxylic acid, a newly designed fluorescence enhancement-type derivatizing reagent for amino compounds.	2010 Mar	20108029

Patents

Sample Use Guides

In Vivo Use Guide

Recommended oral dose of tiemonium (in form of methylsulphate salt) tablet is 2-6 tablets (100-300 mg) daily in divided dosage as required. Tiemonium can be also given as an injection (5 or 10 mg) three times daily, through Intravenous route or Intramuscular route. Suppository: recommended dose is 1 suppository (each suppository contains 20 mg methylsulphate salt) two or three times daily, through rectal route.

Route of Administration: Other

In Vitro Use Guide

Human colon cancer cell lines, LOVO, were incubated in 2 ml of fresh complete medium containing 10(-2) M tiemonium methylsulfate for five days. Under the tested concentration tiemonium methylsulfate lead to a decrease of cell proliferation.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:45:13 GMT 2023` Edited by `admin` on `Sat Dec 16 08:45:13 GMT 2023`
Record UNII	8M71R8MUGX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIEMONIUM MESYLATE

Common Name

English

TIEMONIUM MESILATE

Common Name

English

MORPHOLINIUM, 4-(3-HYDROXY-3-PHENYL-3-(2-THIENYL)PROPYL)-4-METHYL-, METHANESULFONATE (SALT)

Systematic Name

English

MORPHOLINIUM, 4-(3-HYDROXY-3-PHENYL-3-(2-THIENYL)PROPYL)-4-METHYL-, METHANESULFONATE (1:1)

Systematic Name

English

Code System Code Type Description

FDA UNII

8M71R8MUGX